Evidence map›Paper›PMID 33148308›Full record

ArticleTrials2020

The rescue intervention strategy for asthma patients under severe air pollution: a protocol for a single-centre prospective randomized controlled trial.

Xiaoyu Yang, Junjun Huang, Yan Hu, Cuiyan Guo, Xi Wang, Zhao Yang, Tianyu Zhou, Guangfa Wang

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaoyu YangDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Junjun HuangDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China. jaglpc@126.com.ORCID http://orcid.org/0000-0001-5246-0293
Yan HuDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Cuiyan GuoDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Xi WangDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Zhao YangDepartment of Scientific Research, Peking University First Hospital, Beijing, 100034, China.
Tianyu ZhouDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Guangfa WangDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China. wangguangfa@hotmail.com.
Peking University · CN

Funding

Youth clinical research project of Peking University First Hospital 2018CR02
6 · The paper itself

Abstract

backgroundAsthma is a common chronic airway inflammatory disease. Exacerbations of asthma not only accelerate the progression of the disease but also increase the incidence of hospitalization and death. Studies have shown that air pollution is a high-risk factor for asthma exacerbations. However, few treatment strategies have been recommended to reduce the risk of severe air pollution-related asthma exacerbations. METHODS/

designThis is a single-centre, prospective, randomized and standard treatment parallel control clinical trial. Seventy-two asthma patients in the nonexacerbation stage according to GINA guidelines 2017 will be recruited and randomized into the rescue intervention strategy (RIS) group and control group. Original treatments for the participants will include no use of inhaled medicine, the use of short-acting β-agonists (SABA) on demand or the use of budesonide/formoterol (160 μg/4.5 μg/dose, 1-2 dose/time, b.i.d.). The rescue intervention strategy for the RIS group will be budesonide/formoterol plus the original treatment until the severe pollution ends (air quality index, AQI < 200). The control group will maintain the original treatment. The follow-up observation period will last 1 year. The primary outcome is the frequency of asthma exacerbations per year. Secondary outcomes include the mean number of unplanned outpatient visits, emergency visits, hospitalizations, medical costs and mortality caused by asthma exacerbations per patient per year. DISCUSSION: The results of this trial will provide a novel strategy to guide clinical practice in decreasing the risk of asthma exacerbations under severe air pollution.

trial registrationChiCTR ChiCTR1900026757 . Registered on 20 October 2019-retrospectively registered.

Indexed as

Air PollutionAsthmaAdministration, InhalationBronchodilator AgentsBudesonideDrug CombinationsEthanolaminesFormoterol FumarateHumansProspective StudiesRandomized Controlled Trials as TopicBronchodilator AgentsBudesonideDrug CombinationsEthanolaminesFormoterol FumarateAir pollutionAsthmaBudesonide/formoterolExacerbationRescue intervention strategy

Identifiers

PMID33148308
PMCPMC7610012
OpenAlexW3095202234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.